This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyers, C. A. Articles by Brown, P. D. Search for Related Content PubMed PubMed Citation Articles by Meyers, C. A. Articles by Brown, P. D. Social Bookmarking                            What's this?

Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors

From the Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN

Address reprint requests Christina A. Meyers, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 431, Houston, TX, 77030; e-mail: cameyers{at}mdanderson.org

The inclusion of neurocognitive end points in clinical trials of patients with CNS tumors is increasing. Neurocognitive end points are used to understand what cognitive problems exist before treatment to establish a baseline by which the effect of treatment is judged, and to determine whether different treatment regimens improve neurocognitive function due to better tumor control, slow expected neurocognitive deterioration due to the tumor, or have more or less short- and long-term neurotoxicity. However, the use of neurocognitive end points in clinical trials for patients with CNS tumors is in its infancy, so that long-term outcomes are difficult to predict and the ability to determine the effects of different agents and treatment approaches is scant. Including this aspect of patient evaluation in addition to survival and time to tumor progression will yield better risk-versus-benefit assessments as well as provide a basis for improving interventions.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M. Acharya, L.-A. Christie, M. L. Lan, P. J. Donovan, C. W. Cotman, J. R. Fike, and C. L. Limoli Rescue of radiation-induced cognitive impairment through cranial transplantation of human embryonic stem cells PNAS, November 10, 2009; 106(45): 19150 - 19155. [Abstract] [Full Text] [PDF]

				K. Gehring, M. M. Sitskoorn, C. M. Gundy, S. A.M. Sikkes, M. Klein, T. J. Postma, M. J. van den Bent, G. N. Beute, R. H. Enting, A. C. Kappelle, et al. Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial J. Clin. Oncol., August 1, 2009; 27(22): 3712 - 3722. [Abstract] [Full Text] [PDF]

				Y. Cao, C. I. Tsien, P. C. Sundgren, V. Nagesh, D. Normolle, H. Buchtel, L. Junck, and T. S. Lawrence Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction Clin. Cancer Res., March 1, 2009; 15(5): 1747 - 1754. [Abstract] [Full Text] [PDF]

				S. Rosi, M. Andres-Mach, K. M. Fishman, W. Levy, R. A. Ferguson, and J. R. Fike Cranial Irradiation Alters the Behaviorally Induced Immediate-Early Gene Arc (Activity-Regulated Cytoskeleton-Associated Protein) Cancer Res., December 1, 2008; 68(23): 9763 - 9770. [Abstract] [Full Text] [PDF]

				J. S. Smith, E. F. Chang, K. R. Lamborn, S. M. Chang, M. D. Prados, S. Cha, T. Tihan, S. VandenBerg, M. W. McDermott, and M. S. Berger Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas J. Clin. Oncol., March 10, 2008; 26(8): 1338 - 1345. [Abstract] [Full Text] [PDF]

				I. Bosma, L. Douw, F. Bartolomei, J. J. Heimans, B. W. van Dijk, T. J. Postma, C. J. Stam, J. C. Reijneveld, and M. Klein Synchronized brain activity and neurocognitive function in patients with low-grade glioma: A magnetoencephalography study Neuro-oncol, January 1, 2008; 10(5): 734 - 744. [Abstract] [Full Text] [PDF]

				C. A. Meyers, K. R. Lamborn, and M. D. Prados In Reference to Lamborn et al. (Neuro-Oncology. 2008;10:162-170) Neuro-oncol, January 1, 2008; 10(6): 1171 - 1172. [Full Text] [PDF]

				D. Correa, L Maron, H Harder, M Klein, C. Armstrong, P Calabrese, J. Bromberg, L. Abrey, T. Batchelor, and D Schiff Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines Ann. Onc., July 1, 2007; 18(7): 1145 - 1151. [Abstract] [Full Text] [PDF]

				J. Li, S. M. Bentzen, M. Renschler, and M. P. Mehta Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function J. Clin. Oncol., April 1, 2007; 25(10): 1260 - 1266. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, J. C. Buckner, and F. F. Lang CNS Malignancies: At Last, Real Progress J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227. [Full Text] [PDF]

				F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]